Thread by @StephenVLiu

#ASCO20 Update on CASPIAN by Luis Paz-Ares with first report on the durvalumab + tremelimumab arm and update on the durva arm. This was an open label phase III comparing platinum/etoposide vs chemo with durva alone vs chemo with durva and treme in 1L #SCLC. #OncoAlert @IASLC

#ASCO20 Durva/treme arm with slightly more CNS metastases. PCI only permitted on EP arm though some on D+T arm did receive it. While cisplatin or carboplatin permitted, vast majority received carbo (as expected). #OncoAlert #LCSM

#ASCO20 Addition of durvalumab and tremelimumab to EP chemotherapy in #SCLC did not lead to a statistically significant improvement in OS. Median 10.4 vs 10.5 with chemotherapy, OS HR 0.82. There was a numeric increase in 2y OS rate (14.4% vs 23.4%). #OncoAlert #LCSM

#ASCO20 Subgroup analysis, PFS, and duration of response for the durvalumab + tremelimumab arm show interesting trends but overall, this combination did not meet its OS endpoint (unlike durvalumab or atezolizumab alone). #OncoAlert

#ASCO20 Update on the durvalumab arm also provided with 11m more follow up and the OS benefit is maintained. Median OS 12.9 with durva/EP vs 10.5 with EP alone (HR 0.75), 1y OS rate 52.8% vs 39.3%, consistent with earlier report (HR 0.73, 1y 53.7% vs 39.8%). #OncoAlert

#ASCO20 CASPIAN OS results for all three arms on one KM curve. At 2y, durva/treme and durva seem to overlap but earlier, treme quite a bit lower. Could it be the higher toxicity rate (AEs leading to d/c 21.4% vs 10% with durva and 9% with chemo)? #OncoAlert #LCSM @IASLC